Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II
Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is rare hereditary disease caused by changes in the IDS gene and associated deficiency of lysosomal enzyme iduronate-2-sulfatase (I2S). The main treatment scheme for children with MPS II is enzyme replacement therapy (ERT) with recombinant huma...
Saved in:
Main Authors: | Julia G. Levina (Author), Nato D. Vashakmadze (Author), Leyla S. Namazova-Baranova (Author), Elena A. Vishneva (Author), Natalia V. Zhurkova (Author), Kamilla E. Efendieva (Author), Anna A. Alekseeva (Author), Vera G. Kalugina (Author) |
---|---|
Format: | Book |
Published: |
"Paediatrician" Publishers LLC,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Case of Drug Allergy to Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II
by: Julia G. Levina, et al.
Published: (2022) -
Mucopolysaccharidosis type II: Enzyme Replacement Therapy Efficiency
by: Nato D. Vashakmadze, et al.
Published: (2020) -
Results of 14-year-long Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II: Clinical Case
by: Natalia V. Zhurkova, et al.
Published: (2023) -
Intracerebroventricular Enzyme Replacement Therapy in Patients with Neuropathic Form of Mucopolysaccharidosis Type II: to Help Practicing Physician
by: Nataliya V. Zhurkova, et al.
Published: (2024) -
Enzyme Replacement Therapy with Idursulfase in Patients with Mucopolysaccharidosis Type II: Literature Review
by: Nato D. Vashakmadze, et al.
Published: (2021)